ILC 2017: Curing hepatitis C reduces cardiovascular risk

Curing hepatitis C reduces the risk of cardiovascular events in people with compensated cirrhosis, a large French study presented this week at the International Liver Congress in Amsterdam shows. Presenting the findings, Patrice Cacoub of Hôpital Pitié-Salpêtrière, Paris, stressed the importance of thinking of hepatitis C as a systemic disease that affects the heart, the kidneys, blood vessels, the brain and glucose metabolism through mechanisms that are

ILC 2017: European countries restrict access to life-saving treatment for hepatitis C

A review of recent reimbursement data showed considerable variability in access to direct-acting antiviral therapy based on amount of liver scarring and substance use — European Association for the Study of the Liver April 20, 2017, Amsterdam, The Netherlands: Data presented today demonstrate that there are considerable restrictions in the reimbursement of direct-acting antiviral (DAA) therapy across European countries, particularly with respect to th

Hepatitis C Patients at No Elevated Risk of Developing HCC Following DAA Compared to Interferon

Patients were at no elevated risk of developing hepatocellular carcinoma (HCC) after achieving sustained virologic response (SVR) following treatment with direct-acting antiviral therapy (DAA) for hepatitis C compared to interferon therapy, according to results of a meta-analysis reported at the 2017 International Liver Congress (ILC). The data reflected that there was no difference in liver cancer risk following cure with either therapy. However, achievi

ILC 2017: Four new EASL clinical practice guidelines on the management of liver diseases presented at The International Liver Congress 2017

April 19, 2017, Amsterdam, The Netherlands: The European Association for the Study of the Liver (EASL) today announced that four new Clinical Practice Guidelines (CPGs) will be presented at The International Liver Congress™ 2017 in Amsterdam, The Netherlands, and published in the Journal of Hepatology, EASL’s official journal. CPGs define the use of diagnostic, therapeutic and preventive modalities, including non- invasive and invasive procedures, in the

U.S.: Kids With Hepatitis C Get New Drugs And Coverage May Prove Easier Than For Adults

With the approval this month of two drugs to treat hepatitis C in children, these often overlooked victims of the opioid epidemic have a better chance at a cure. Kids may have an easier time than adults getting treatment approved, some experts say. Medicaid programs and private insurers have often balked at paying for the pricey drugs for adults, but stricter Medicaid guidelines for kids may make coverage more routine. The two drugs approved for pediat

WHO prequalifies first generic active ingredient for hepatitis C medicines

On 31 March 2017, WHO for the first time prequalified a generic active pharmaceutical ingredient (API) for hepatitis C – sofosbuvir. Sofosbuvir is an essential ingredient for new, highly effective medicines to treat hepatitis C called direct active antivirals (DAAs). The prequalified product’s manufacturer is Mylan Laboratories Ltd - INDIA. The emergence of DAAs in 2014 gave new hope to the 80-110 million people suffering from chronic hepatitis C, a disea

The Week in Review: March 31, 2017 – April 7, 2017

Friday, April 7, 2017 News Recap Canada Effective April 2017, Alberta Health has expanded access to treatments for hepatitis C in line with what the provinces of British Columbia, Ontario, Saskatchewan, and Québec have just done (Alberta expands drug coverage for hepatitis C patients). As Dr. Shafran, who is clearly worried about continued restrictions, says, “The funders have now opened the doors to let us treat people with mild liver disease … if ...

U.S.: FDA approves two hepatitis C drugs for pediatric patients

The U.S. Food and Drug Administration today approved supplemental applications for Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir) to treat hepatitis C virus (HCV) in children ages 12 to 17. Harvoni and Sovaldi were previously approved to treat HCV in adults. These are the first direct-acting antiviral treatments approved for children and adolescents with HCV. Direct-acting antiviral drugs reduce the amount of HCV in the body by preventing th

Wiping out hepatitis C: Alberta doctor explains access to game-changing drug for patients

More Albertans suffering from hepatitis C will receive treatment thanks to public funding for new therapies, says Stephen Shafran, a University of Alberta professor of medicine who specializes in the virus. He spoke Wednesday to Postmedia about a game-changing drug and how Alberta can help eradicate hepatitis C. Here’s a condensed, edited version the interview. Q: Alberta Health has made the drug Epclusa available to more patients. The treatment is a p

Alberta expands drug coverage for hepatitis C patients

“Effective April 2017, Alberta Health has agreed to pay for several new therapies for the treatment of hepatitis C, the most important of which is a medicine called Epclusa, which contains two anti-viral drugs,” said Stephen Shafran, a professor of medicine at the University of Alberta. Epclusa, a drug for hep C with a near 100 per cent cure rate, is now going to be covered by Alberta Health. “This should give people hope that they can be cured,” Shafr